High-dose chemotherapy, with or without radiotherapy, followed by autologous stem-cell rescue is used increasingly for the intensification of first remission in acute myeloblastic leukemia (AML). However, these treatments have been l i m i t e d t o young patients due to the increased risks of regimen-related toxicities and m o r t a l i with age. Several investigators have recently published the upper age limit for autologous bone marrow transplant (ABMT) in AML because of encouraging results. The resutts of ABMT for AML were studied in 11 1 patients a50 years of age intensified in first remission. Median age at transplant was 53 years (range, 50 t o 63 years). F i i patients were conditioned with total body irradiation and 61 with polychemotherapy: 23 with busulfancyclophowhamide, 11 with the University College Hospital (UCH; London, UK) regimen, 6 with BAVC, and 21 with various other treatments. Marrow was purged in only 11 cases.
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Results were compared with 786 ABMTs performed for AML
A UTOLOGOUS BONE marrow transplantation (ABMT)
is a therapeutic option used to intensify remission in adult patients with acute myeloblastic leukemia (AML)."13 This approach is currently under study in several prospective randomized trials comparing ABMT and chemotherapy in patients aged less than 50 years in first remi~sion.'*~*'~ In most series, the median age of the ABMT recipients is between 30 and 35 years, younger than the median age of the population of patients affected by this disease. To evaluate the feasibility of ABMT in patients aged 2 5 0 years, we analyzed results in patients reported to the European Bone Marrow Transplant Group (EBMT) from January 1,1980, to December 3 1,199 1.
We compared the outcomes in patients aged less than and greater than 50 years.
MATERIALS AND METHODS

Patients.
Data from 11 1 patients with AML autografted in first remission (CR1) and aged over 50 years were reported to the EBMT registry between January 1, 1980, and December 31, 1991. Table 1 lists the institutions reporting data. The closing date for this analysis was September 30, 1992. During the same period, 786 patients aged less than 50 years were reported to the registry for the same indications. The median age of the older group was 53 years (range, 50 to 63 years). The median interval between diagnosis and ABMT was 196 days (range, 70 to 665 days), and the median interval between CRl and transplant was 147 days (range, 7 to 637 days).
Statistical methods. Leukemia-free survival (LFS) was defined as survival without evidence of leukemia. Treatment-related mortality (TRM) was defined as death while in complete remission; patients were censored at time of relapse or last follow-up. For the relapse rate, patients dying of either direct toxicity of the procedure or any other cause not related to leukemia were censored. All analyses were performed using a BMDP statistical package. Kaplan-Meier curves were calculated using the product limit m e t h~d . '~ Comparisons of survival probabilities were performed using the logrank test (Mantel-COX). Curves in the figures were stopped when fewer than three patients remained at risk. years). For AML in first remission, the probability of leukemia-free survival (LFS) at 4 years was 34% f 5% for patients aged 50 years or more and 4 3 % f 2% for patients less than 50 years of age (P = .004), with a survival probability of 35% f 6% and 4 8 % e 29'0, respectively (P = .004). The probability of relapse was not significantly different between the two groups 62%0 f 7% Y 50% f 24/01, but transplant-related mort a l i was significantly higher in the older age group (28% & 5% Y 14% f 2%; P C .000l) and mainly due t o infectious complications. In a multivariate analysis, age less than 50 years wes a favorable risk factor for LFS, treatment-related mortality (TRM), and survival but not for relapse incidence. These data suggest that ABMT should be considered in older AML patients.
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Patient-, disease-, and treatment-related variables were compared between the two age groups using the x* statistic for categorical variables. Variables differing significantly (P < .05) or recognized as potential prognostic factors were included as covariates in a multivariate analysis comparing outcome of patients at different ages. Multivariate analysis used Cox proportional hazard regression to compare risk of relapse, TRM, LFS, and survival between the two cohorts.18 Table 2 and pretransplant regimens in Table  3 . Comparisons of all characteristics pretransplant and peritransplant in the two populations (aged less than 50 years, aged 250 years) showed similar distributions for sex ratio, French-American-British (FAB) classification, prognostic factors, interval from diagnosis to CR1, CR1 to ABMT, and pretransplant regimens.
RESULTS
Pretransplant parameters are summarized in
The two populations differed for the nature of the graft, with more transplants with peripheral blood stem cells (PBSC) and less purge in older patients not statistically different between both groups, nor was ( P = .04 and P = .001, respectively). We have no data recovery of platelet count to over 50 X 109/L ( P = .63 concerning any difference in the amount of induction or and .09, respectively). postinduction therapy between the two groups of patients, LFS is shown in Fig 1, with a probability of 34% +-5% but the percentage of patients reaching complete remission at 4 years for the older group and 43% 2 2% for patients after 40 days did not differ between both groups. Recovery below 50 years of age ( P = .W). time of the granulocyte count to over 0.5 X 109/L was Figure 2 shows the probability of relapse of the two groups: 52% 5 7% at 4 years for older patients versus 50%
5 3% at 473 weeks for the younger group (P = .39).
Finally, the probability of TRM is significantly higher for the older group (28% 2 5% v 14% 2 5% at 4 years; P < .OOOl ; Fig 3) , and the overall survival is 35% ? 6% at 4 years for the older group versus 48% 5 3% for the younger group (P = .004). Table 4 summarizes the causes of deaths in each category of age. Increased risk of toxic deaths in the older group was mainly due to infectious complications.
In multivariate analysis ( Table 5) , age less than 50 years was a favorable risk factor for LFS, TRM, and survival.
DISCUSSION
High-dose chemotherapy, with or without total body irradiation (TBI), followed by stem-cell rescue has become a frequent therapy for intensification of remission in patients with acute AML."l6 Until recently, high-dose treatments have been limited to younger patients due to fear of an increased risk of treatment-related toxicity and mortality with age. Several randomized studies have been initiated to evaluate intensification and ABMT'.6.9.'5 but only for patients aged less than 45 or 50 years. In most published reports, as well as in the EBMT registry, the median age of the patients is between 30 and 35 years, which is much lower than the median age of AML patients. Therefore, we decided to analyze retrospectively the results of such a therapeutic approach for older patients in first remission. The EBMT database contained 11 1 AML patients aged 250 years intensified in their first remission by high-dose therapy followed by autologous stem-cell rescue. The distribution of all pretransplant and peritransplant parameters are comparable in the two groups (aged less than 50 years v aged 2 5 0 years), with a notable exception for purge and percentage of transplants with PBSC. In the older group, only 9.9% patients had a marrow purge in vitro versus 23.4% in the younger group, and this difference was partly due to a more frequent use of PBSC (11.7% v 5.5%), probably in an effort to enhance engraftment. However, the analysis showed no difference in relapse incidence, but rather indicated a higher probability of transplant-related mortality in the older group, leading to a lower survival. The question of a possible decrease of TRM in patients receiving a non TB1 pretransplant regimen could not be explored in this retrospective study because of the small number of patients. We had arbitrarily chosen the cut-off at 50 years; however, we have subsequently checked that TRM was only increased after 50 years of age, results being not modified when age was analyzed as a continuous variable. These results confirm the feasibility of high-dose therapy followed by autologous rescue in elderly patients. Similarly, allogeneic BMTs have been shown also to be feasible in patients aged greater than 40 years.' The data we present must be interpretated with caution, confirmed in prospective trials, and then compared with intensification of chemotherapy in a similar way as for current trials for younger patients. Two questions remain: first, the upper age limit, which may reach 60 years in otherwise eligible candidates; and second, the nature of the transplant to use: marrow (purged or not) or PBSC. 
